Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
Total Valuation
Outlook Therapeutics has a market cap or net worth of $40.45M. The enterprise value is $71.13M.
Market Cap$40.45M
Enterprise Value$71.13M
Share Statistics
Outlook Therapeutics has 32.62M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding32.62M
Owened by Insiders27.93%
Owened by Instutions1.35%
Financial Efficiency
Outlook Therapeutics’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is <0.01%.
Return on Equity (ROE)<0.01%
Return on Assets (ROA)>-0.01%
Return on Invested Capital (ROIC)<0.01%
Return on Capital Employed (ROCE)<0.01%
Revenue Per Employee$0
Profits Per Employee-$2,035,254.826
Employee Count23
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Outlook Therapeutics is -1.31. Outlook Therapeutics’s PEG ratio is -0.01.
PE Ratio-1.31
PS Ratio0.00
PB Ratio>-0.01
Price to Fair Value>-0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio-0.01
Income Statement
In the last 12 months, Outlook Therapeutics had revenue of $0.00 and earned -$46.81M in profits. Earnings per share was -$8.26.
Revenue$0.00
Gross Profit$0.00
Operating Income-$82.99M
Pretax Income$17.38T
Net Income-$46.81M
EBITDA9.67M
Earnings Per Share (EPS)-8.26
Cash Flow
In the last 12 months, operating cash flow was -$10.97T and capital expenditures $0.00, giving a free cash flow of -$10.97T billion.
Operating Cash Flow-$10.97T
Free Cash Flow-$10.97T
Free Cash Flow per Share-$336.21K
Dividends & Yields
Outlook Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-69453204.06%
Earnings Yield-76.09%
Stock Price Statistics
Beta-0.20
52-Week Price Change-83.99%
50-Day Moving Average1.50
200-Day Moving Average4.35
Relative Strength Index (RSI)33.90
Average Volume (3m)428.13K
Important Dates
Outlook Therapeutics upcoming earnings date is May 14, 2025, TBA.
Last Earnings DateFeb 14, 2025
Next Earnings DateMay 14, 2025
Ex-Dividend Date―
Financial Position
Outlook Therapeutics as a current ratio of 0.64, with Debt / Equity ratio of >-0.01
Current Ratio0.64
Quick Ratio0.64
Debt to Market Cap0.30
Net Debt to EBITDA-0.21
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Outlook Therapeutics has paid $2.80K in taxes.
Income Tax$2.80K
Effective Tax Rate0.00%
Enterprise Valuation
Outlook Therapeutics EV to EBITDA ratio is -1.59, with an EV/FCF ratio of >-0.01.
EV to Sales0.00
EV to EBITDA-1.59
EV to Free Cash Flow>-0.01
EV to Operating Cash Flow>-0.01
Balance Sheet
Outlook Therapeutics has $5.70T in cash and marketable securities with $31.03M in debt, giving a net cash position of -$5.70T billion.
Cash & Marketable Securities$5.70T
Total Debt$31.03M
Net Cash-$5.70T
Net Cash Per Share-$174.82K
Tangible Book Value Per Share-$3.94M
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Outlook Therapeutics is $10.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.00
Price Target Upside624.64%
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast
EPS Growth Forecast-29.01%